Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the target of a large increase in short interest in January. As of January 30th, there was short interest totaling 409,394 shares, an increase of 28.3% from the January 15th total of 319,014 shares. Based on an average daily volume of 3,466,499 shares, the short-interest ratio is currently 0.1 days. Approximately 17.7% of the shares of the stock are short sold. Approximately 17.7% of the shares of the stock are short sold. Based on an average daily volume of 3,466,499 shares, the short-interest ratio is currently 0.1 days.

Dermata Therapeutics Stock Performance

Dermata Therapeutics stock traded down $0.06 during trading on Monday, reaching $1.29. The company had a trading volume of 171,083 shares, compared to its average volume of 1,866,691. Dermata Therapeutics has a 12-month low of $1.29 and a 12-month high of $23.70. The stock’s 50 day moving average price is $2.21 and its two-hundred day moving average price is $3.75. The firm has a market capitalization of $3.66 million, a price-to-earnings ratio of -0.17 and a beta of 0.54.

Dermata Therapeutics (NASDAQ:DRMA) last announced its quarterly earnings results on Friday, November 14th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.59) by ($0.06).

Analyst Upgrades and Downgrades

A number of research firms recently commented on DRMA. Wall Street Zen raised Dermata Therapeutics to a “sell” rating in a research note on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Dermata Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Hedge Funds Weigh In On Dermata Therapeutics

A hedge fund recently bought a new stake in Dermata Therapeutics stock. Clear Street Group Inc. acquired a new stake in Dermata Therapeutics, Inc. (NASDAQ:DRMA) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned approximately 0.60% of Dermata Therapeutics at the end of the most recent reporting period. 8.67% of the stock is currently owned by institutional investors and hedge funds.

About Dermata Therapeutics

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.